Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 19/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4461462 | 1.00 | P2RX7 (0.44) | P2RX7 | |
| SCHEMBL30684468 | 0.86 | P2RX7 (0.35) | P2RX7 | |
| SCHEMBL13949148 | 0.81 | P2RX7 (0.45) | P2RX7 | |
| SCHEMBL159149 | 0.81 | ACE (0.47) | P2RX7 | |
| SCHEMBL13949149 | 0.81 | P2RX7 (0.45) | P2RX7 | |
| SCHEMBL647325 | 0.81 | ACE (0.47) | P2RX7 | |
| SCHEMBL1850331 | 0.81 | ACE (0.47) | P2RX7 | |
| SCHEMBL1587617 | 0.81 | ACE (0.47) | P2RX7 | |
| SCHEMBL18101128 | 0.81 | P2RX7 (0.45) | P2RX7 | |
| SCHEMBL7398033 | 0.79 | P2RX7 (0.44) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117500786-A | TEAD inhibitors | 奥赖恩公司 | 2024-02-02 | — | — | CN | claimed |
| EP-4631573-A2 | TEAD INHIBITORS | Orion Corporation (FI) | 2025-10-15 | — | — | EP | disclosed |
| EP-4323338-B1 | TEAD INHIBITORS | ORION CORP (FI) | 2025-10-08 | — | — | EP | disclosed |
| US-20240246908-A1 | TEAD INHIBITORS | ORION CORPORATION (FI) | 2024-07-25 | — | — | US | disclosed |
| EP-4323338-A1 | TEAD INHIBITORS | Orion Corporation (FI) | 2024-02-21 | — | — | EP | disclosed |
| CN-117500786-A | TEAD inhibitors | 奥赖恩公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2023211997-A1 | ANTIVIRAL COMPOUNDS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2022219246-A1 | TEAD INHIBITORS | ORION CORPORATION (FI) | 2022-10-20 | — | — | WO | disclosed |
| WO-2022219246-A1 | TEAD INHIBITORS | ORION CORPORATION (FI) | 2022-10-20 | — | — | WO | disclosed |
| CN-113307758-B | P2X7 receptor targeting probe precursor labeled by medical radioactive isotope | 复旦大学 | 2022-10-14 | — | — | CN | disclosed |
| WO-2009074518-A1 | COMBINATIONS OF PROLINAMIDE P2X7 MODULATORS WITH FURTHER THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2009-06-18 | — | — | WO | disclosed |
| EP-1536797-B1 | 1-AMIDO-4-PHENYL-4-BENZYLOXYMETHYL-PIPERIDINE DERIVATIVES AND RELATED COMOUNDS AS NEUROKININ-1 (NK-1) ANTAGONSISTS FOR THE TREATMENT OF EMESIS, DEPRESSION, ANXIETY AND COUGH | SCHERING CORP (US) | 2007-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246908-A1 | TEAD INHIBITORS | TEAD3, TEAD1, TEAD2 | P2RX7 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.